Chembio Diagnostics - CEMI Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CEMI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CEMI, but not buy additional shares or sell existing shares.
View CEMI analyst ratings or view top-rated stocks.

Chembio Diagnostics' stock was trading at $0.2197 at the start of the year. Since then, CEMI shares have increased by 59.4% and is now trading at $0.3501.
View the best growth stocks for 2023 here.

Chembio Diagnostics saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 1,580,000 shares, a decrease of 20.2% from the December 31st total of 1,980,000 shares. Based on an average trading volume of 412,400 shares, the days-to-cover ratio is presently 3.8 days.
View Chembio Diagnostics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our CEMI earnings forecast.

Chembio Diagnostics, Inc. (NASDAQ:CEMI) announced its earnings results on Thursday, November, 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $11.20 million for the quarter. Chembio Diagnostics had a negative net margin of 60.93% and a negative trailing twelve-month return on equity of 129.14%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), NovoCure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and ReWalk Robotics (RWLK).

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

Shares of CEMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CEMI stock can currently be purchased for approximately $0.35.

Chembio Diagnostics (NASDAQ:CEMI) has a market capitalization of $12.85 million and generates $47.82 million in revenue each year. The company earns $-33,900,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

The company employs 337 workers across the globe.

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The official website for the company is www.chembio.com. The company can be reached via phone at (631) 924-1135, via email at investor@chembio.com, or via fax at 631-924-2065.